Market Analysis of Seasonal Influenza Vaccination in Estonia, Latvia and Lithuania Represents Progressive Growth until 2022

Albany, New York, March 10, 2017: It is well known that a lot of the illness and death caused by the influenza virus can only be prevented by a yearly influenza vaccine. According to a new report, focusing on the market of seasonal influenza vaccination analyzes that the growing children and aging population in Baltic regions have augmented the demand for the vaccinations. This study is headlined as ‘Seasonal Influenza Vaccination Market in Baltic Countries’ which delivers a comprehensive examination of the market, by considering the forecast period of 2011 to 2022.

Request for Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=998974

The major focus of the report is on Baltic countries, which is a northeastern region of Europe containing the countries of Latvia, Lithuania and Estonia on the eastern shores of Baltic Sea. According to the key findings of the report, among these countries, Lithuania is having the highest seasonal influenza vaccine market share followed by Latvia and Estonia. One of the primary reasons for this growth is that, Latvia is the only Baltic country with a positive recommendation for the young. They provide Trivalent Influenza Vaccine (TIV) free of charge to all children aged below 6 months. In terms of children vaccination, Lithuania & Latvia hold nearly 70 % market share in 2016 whereas, in adult vaccination segments, these two will share more than 95 % market share by 2022.

Moreover, it is also predicted that by the end of 2022, the market for seasonal influenza vaccine will increase expressively due to rising healthcare expenditure share of the Baltic countries GDP and vaccine manufacturers plan to increase flu vaccine production.

Moving further, the report describes that, influenza is a contagious respiratory disease which causes thousands of deaths, hospitalizations and disabilities each year. This flu is mostly spread through droplets from infected people, flu cough, sneeze or talks.

Additionally, all the 3 countries in the report have been studied from 2 viewpoints, which includes:

• Number of vaccinated population (Child & Adult)
• Overall seasonal influenza vaccine market (Child & Adult)

Browse Full Report with TOC: http://www.marketresearchhub.com/report/seasonal-influenza-vaccination-market-in-lithuania-estonia-latvia-baltic-countries-by-child-adult-forecast-report.html

The burden of influenza amongst children is substantial, with attack rates reaching 20%-30% of the population on average in each influenza season. In that case, Influenza vaccine normally known as the flu shot and is used for safety against influenza virus. An influenza vaccine is a grouping of three viruses types that is, influenza type A with H3N2 virus strain, influenza type A with H1N1 virus strain and influenza type B virus strain. The seasonal flu vaccine protects against the influenza viruses that research indicates will be most common during the upcoming season.

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us

90 State Street,
Albany, NY 12207,
United States
Toll Free: 866-997-4948 (US-Canada)
Tel: +1-518-621-2074
Email : press@marketresearchhub.com

Follow us on:
Twitter: twitter.com/MktResearchHub
LinkedIn: www.linkedin.com/company/market-research-hub
Facebook: www.facebook.com/MarketResearchHub/

This release was published on openPR.